CEO Update | 1 August 2022

Innovative UK Genomics companies are vital to the future wealth of our nation

Last week we released our Genomics Nation 2022 report, in partnership with the Medicines Discovery Catapult and Wellcome Sanger Institute, which showcases the strengths and opportunities of this vibrant UK ecosystem of entrepreneurs, spin-outs and scale-ups.

The new data shows that UK genomics companies raised £1.9 billion in venture investment and £35.7 million in public grants since 2017, demonstrating the strength of this innovative sector.

Innovative UK Genomics companies are vital to the future wealth of our nation. With the right investment, skilled people and partnership working with the NHS family, UK small and medium-sized enterprises are ideally placed to be key global players in the growing subsectors within genomics such as functional genomics, epigenetics, transcriptomics and pharmacogenomics.  

The application and industrialization of this technology is transforming both healthcare and the pharmaceutical industry. Our growing sector needs great people who can use computational and data science skills to deliver our transforming health projects.

Key findings from the report include:

  • the genomics sector consists of 121 companies employing over 3,500 highly skilled people
  • has a market cap of over £3.5 billion based on deals since 2017
  • is young and growing, with half at early or seed stage
  • has a higher proportion of spin-outs (34%) compared to other sectors (2.7%)
  • relies on a range of skilled professionals, with 70% saying it was challenging to recruit for computational and data science skills.

BIA response to DHSC consultation on the future strategy for batch testing of medicines in Great Britain

The BIA has responded to the Department of Health and Social Care (DHSC) consultation on the future strategy for batch testing of medicines in Great Britain. The consolidated BIA response was developed with input from our Regulatory Affairs Advisory Committee. It is important that the consultation outcome supports the ambitions of the Life Sciences Vision and ensures that the UK retains and grows its reputation as a world-leading base for innovation and investment in R&D, while protecting patient safety and access to medicines, and maintaining globally harmonised standards.

Steve circle.png

 

 

Steve Bates OBE
CEO, BioIndustry Association


More news and updates

CEO Update - 25 March 2024

I’m delighted to be opening PULSE this morning. It is a free three-day leadership and entrepreneurship training programme for up-and-coming life sciences entrepreneurs that we’ve developed and delivered with the Francis Crick Institute. Read on for the latest on EU biotech initiatives, Biosecurity Leadership Council and boost for UK cell and gene therapy.

AI in life sciences: an evolving risk landscape

In this article, Marsh’s Life Sciences industry practice leader Jenny Yu and experts from Kennedys take a look at the topic of AI in the life sciences sector, the associated risks regulation and potential liability issues, as well as how companies can seek to ‘future-proof’ themselves in the face of rapid change.

CEO Update - 18 March 2024

A year ago, the life sciences sector faced a significant challenge with the SVB UK collapse. This event threatened to disrupt vital research and development for many companies. Today, we're taking a moment to reflect on that experience and share valuable resources to help us all build a more resilient future. 

Member spotlight: Meet OMass Therapeutics

In this blog, Ros Deegan, CEO of OMass Therapeutics, a member of the BIA Board and a member of the Prime Ministers 2024 Business Council, shares how the company is pioneering new approaches to drug discovery, targeting challenging diseases with their advanced platform.

More within